Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series

EJHaem Pub Date : 2024-08-06 DOI:10.1002/jha2.913

Nini Aung, Margaret Bowers, Gillian Brearton, Andrew Charlton, Joanne Craig, Jonathan Cullis, Ray Dang, David Donaldson, Mary Drake, Rachel Hall, Elizabeth Parkins, Jane Tighe, Ceri Bygrave, Oonagh Sheehy

{"title":"Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series","authors":"Nini Aung, Margaret Bowers, Gillian Brearton, Andrew Charlton, Joanne Craig, Jonathan Cullis, Ray Dang, David Donaldson, Mary Drake, Rachel Hall, Elizabeth Parkins, Jane Tighe, Ceri Bygrave, Oonagh Sheehy","doi":"10.1002/jha2.913","DOIUrl":null,"url":null,"abstract":"<p>This report describes the characteristics and outcomes of 18 heavily pretreated patients with multiple myeloma (MM) who were subsequently treated with selinexor. This is a case series of 18 patients with MM who were treated with selinexor and dexamethasone (Sd) or selinexor, bortezomib, and dexamethasone (SVd) in 12 hospitals in the UK between 2019 and 2021. Eight patients received Sd and 10 patients received SVd. Patients received a median of five prior treatment lines, including immunomodulatory agents in 94% and proteasome inhibitors in 94%. Ten patients (55%) had triple-class refractory disease. Six of the 12 evaluable patients achieved ≥partial response. The median progression-free survival was 5.6 months, which was higher with SVd (5.7 months) than with Sd (2.1 months). The results support a treatment benefit of selinexor in heavily pretreated patients and support the notion that selinexor may overcome resistance to prior therapies, with no new safety concerns arising.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 5","pages":"987-991"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.913","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

This report describes the characteristics and outcomes of 18 heavily pretreated patients with multiple myeloma (MM) who were subsequently treated with selinexor. This is a case series of 18 patients with MM who were treated with selinexor and dexamethasone (Sd) or selinexor, bortezomib, and dexamethasone (SVd) in 12 hospitals in the UK between 2019 and 2021. Eight patients received Sd and 10 patients received SVd. Patients received a median of five prior treatment lines, including immunomodulatory agents in 94% and proteasome inhibitors in 94%. Ten patients (55%) had triple-class refractory disease. Six of the 12 evaluable patients achieved ≥partial response. The median progression-free survival was 5.6 months, which was higher with SVd (5.7 months) than with Sd (2.1 months). The results support a treatment benefit of selinexor in heavily pretreated patients and support the notion that selinexor may overcome resistance to prior therapies, with no new safety concerns arising.

Abstract Image

查看原文本刊更多论文

赛来昔洛联合地塞米松与或不联合硼替佐米治疗重度预处理多发性骨髓瘤：病例系列

本报告描述了18名接受过大量预处理的多发性骨髓瘤（MM）患者的特征和预后，这些患者随后接受了赛来昔洛治疗。这是一个病例系列，收集了2019年至2021年期间在英国12家医院接受赛来昔诺和地塞米松（Sd）或赛来昔诺、硼替佐米和地塞米松（SVd）治疗的18名多发性骨髓瘤患者的病例。8名患者接受了Sd治疗，10名患者接受了SVd治疗。患者之前接受的治疗中位数为五种，其中94%为免疫调节剂，94%为蛋白酶体抑制剂。10名患者（55%）患有三类难治性疾病。在12例可评估的患者中，有6例获得了≥部分应答。无进展生存期中位数为 5.6 个月，SVd（5.7 个月）高于 Sd（2.1 个月）。研究结果表明，西利昔诺对重度预处理患者有治疗效果，并支持西利昔诺可克服既往疗法耐药性的观点，且未出现新的安全性问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量